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Abstract
Background: Vitamin D deficiency has been linked to an increased risk of asthma. This study aimed to quantify the
effect of early life vitamin D status on asthma and wheeze later in life.
Methods: PubMed, Embase, CINAHL, and CNKI databases, the Cochrane Central Register of Controlled Trials, and
Google Scholar were searched up to July 2017. We included randomized controlled trials (RCTs) and cohort studies
with vitamin D level in blood (maternal or cord or infant) or intake (maternal intake during pregnancy or infant
intake) and asthma and/or wheeze. Two reviewers independently extracted data. Fixed- and random-effects models
were used to summarize the risk estimates of comparisons between highest vs. lowest vitamin D categories.
Results: Of the 1485 studies identified, three RCTs and 33 cohort studies were included. We did not include the
RCTs (1619 participants) in the meta-analysis as the comparators and outcome definitions were heterogenous.
Three RCTs reported a non-statistically significant effect of vitamin D supplementation during pregnancy on
offspring wheeze/asthma at 3 years of age. Pooled estimates of cohort studies suggest no association between
antenatal blood vitamin D levels or vitamin D intake and offspring asthma assessed either > 5 years or ≤ 5 years.
The estimate for blood vitamin D remained unchanged when two studies assessing asthma in adulthood were
excluded, but a significant inverse association emerged between vitamin D intake and childhood asthma. We found
no association between antenatal vitamin D level and wheeze. On the other hand, vitamin D intake during
pregnancy may have a protective effect against wheeze.
Conclusions: The pooled estimates from cohort studies show no association between antenatal blood vitamin D
level and asthma/wheeze in later life. Whereas, the pooled estimates from cohort studies suggest that antenatal
vitamin D intake may have an effect on childhood asthma > 5 years or childhood wheeze. The inconsistent results
from studies assessing vitamin D either in blood or intake may be explained by previously reported non-linear
association between blood vitamin D3 and childhood asthma. Further trials with enough power and longer follow-
up time should be conducted to confirm the results.
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Background
Asthma is an important cause of disability and a major
worldwide public health concern. The prevalence of
asthma in developed countries rose rapidly in the 1960s
and has remained high since [1]. More recently, the
same rising trend has been observed in developing coun-
tries [2]. While asthma affects people of all ages, the
surge among children has been most marked [3].
Among the environmental factors that contribute to
asthma, vitamin D status has generated increasing interest
for the vitamin’s purported immunomodulatory properties.
Clinically, serum calcifediol [25(OH)D] is used as a
marker of vitamin D level [4]. In various populations calci-
fediol levels in cord blood are strongly correlated with ma-
ternal levels during pregnancy [5], with maternal
calcifediol as the source of the fetal vitamin D pool [6].
Vitamin D deficiency in pregnant women and infants is
common worldwide, including both developed and devel-
oping countries, ranging from 45 to 90% in pregnant
women and 61–94% in infants [5, 7–9]. Based on growing
epidemiological evidence, vitamin D deficiency has been
linked to an increased risk of respiratory infections and
asthma [10]. However, it is still unclear if and to what ex-
tent antenatal or early postnatal vitamin D deficiency
would affect the development of wheeze or asthma later in
life. Previous reviews on vitamin D supplementation during
pregnancy have given conflicting messages [11–13].
Given that there have been further published studies
(including trials), we undertook a systematic review aim-
ing to address whether antenatal or early postnatal vita-
min D status (including intake and blood level, both
maternal and in infant) has any impact on the risk of de-
veloping asthma and wheeze later in life.
Methods
We followed the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) [14] and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [15] when conducting and presenting this system-
atic review and meta-analysis. PRISMA and MOOSE check-
list can be found in Additional file 1: Supplement 1. The
review protocol was registered previously with the Inter-
national Prospective Register of Systematic Reviews (PROS-
PERO Registration No. CRD42013005559) [16]. The initial
protocol considered asthma/wheeze, allergic rhinitis, atopic
dermatitis (eczema), food allergy and atopic sensitization,
but here we focus on asthma and wheeze.
Data sources and searches
We conducted a systematic literature search using
PubMed, Embase, CINAHL, and CNKI (in Chinese) da-
tabases and Google Scholar for studies published up to
19th July 2017 and the Cochrane Central Register of
Controlled Trials that reported data on antenatal or
early postnatal vitamin D status or intervention and
asthma and wheezing in children or adults. Details of
the search strategy are provided in Additional file 1:
Supplement 2.
Study selection
The present systematic review focused on the effect of
vitamin D level in blood (maternal or cord or infant) and
intake (maternal intake during pregnancy or infant intake)
on asthma and wheeze. We included randomized con-
trolled trials (RCTs), quasi-randomized controlled trials,
non-randomized controlled trials, prospective and retro-
spective cohort studies that measured maternal vitamin D
status during any trimester of pregnancy or cord blood or
offspring vitamin D status during infancy, and having
asthma or wheeze during childhood or adulthood as out-
comes, which (i) were diagnosed by doctors (including
parental or self-reports), or (ii) required the use of asthma
medication, or (iii) as assessed by the International Study
of Asthma and Allergies in Children (ISAAC) question-
naire (Additional file 1: Supplement 3). Two reviewers (SS
and WX) independently screened the titles and abstracts
and identified potentially relevant publications according
to the selection criteria, of which full text was obtained
and read (online Additional file 1: Supplement 4). The ref-
erence lists of all papers of interest were scrutinized to ob-
tain other relevant articles. Disagreements over inclusion
were resolved through consensus, and where necessary, a
third reviewer (JL) was involved.
Data extraction and risk of Bias assessment
The same reviewers independently extracted data using a
standard data extraction form. We collected data on the
number of subjects with and without asthma or wheeze in
the antenatal or early postnatal vitamin D exposed/inter-
vention and non-exposed/control groups; risk estimates
(crude and/or adjusted odds ratios [ORs], relative risks
[RRs] and hazard ratios [HRs]) and the corresponding 95%
confidence intervals (CIs) at any available age end point.
Furthermore, we recorded information on the population,
geographical location, inclusion and exclusion criteria,
interval of follow up, exposure measurement, outcome def-
inition, measurement and window of assessment, and con-
founders (more details in Additional file 1: Supplement 5).
Study authors were contacted when missing data was an
issue. Disagreements on data extraction were checked
against the original articles and/or resolved by a third
reviewer. The data extracted were entered into Review
Manager software and were double checked by two
reviewers. Risk of bias was assessed using the tool recom-
mended by the Cochrane Collaboration [17, 18]. Two re-
viewers independently rated the risk of bias for each study
as high, low, or unclear (‘Definitely yes’ in the tool was con-
sidered as ‘low’ risk, ‘Definitely no’ as ‘high’ risk, ‘unclear’
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comprised ‘probably yes’ and ‘probably no’ as specified in
the tools [18]). Disagreements were resolved by discussion
or by involving a third reviewer. Each cohort study was
classified into one of the following categories: high (more
than two criteria not applied/met); moderate (one or two
criteria not applied/met or unclear); and low risk of bias
(all criteria applied/met).
Data synthesis and analysis
We pooled the original risk estimates as reported (most
being ORs) and used adjusted risk estimates where avail-
able. When only frequency distributions were provided,
we calculated unadjusted ORs and their 95% CIs from
the outcome distribution of exposed and non-exposed
groups. Where outcome assessment was done in mul-
tiple time points in a study, we chose the one with the
longest follow-up period or the time point when the age
of the participants was comparable to other studies.
We pooled the risk estimates from each study that
compared the risk in the highest vitamin D concentra-
tion or intake category with the lowest (which is the
referent category), and also the risk in vitamin D suffi-
ciency (≥75 nmol/L [4]) with deficiency (< 50 nmol/L ac-
cording to the Institute of Medicine (IOM) definition
[19]). As it could be difficult to diagnose asthma in
children below 5 years of age, we stratified the studies
on asthma according to the age of outcome assessment
(> 5 years and ≤ 5 years). For exploring the association
between blood vitamin D status and childhood asthma,
a sensitivity analysis was performed by excluding the
studies assessing the outcome in adulthood. We con-
tacted the authors of the studies (n = 8) that had differ-
ent cut-off values, and asked them to re-analyze their
data according to the above categorization scheme. Of
the eight authors contacted, four responded and pro-
vided additional data [20–23].
Both fixed-effects and random-effects models were
used to summarize the effect sizes. Heterogeneity was
evaluated by using the Q (P > 0.10 in the Chi2 test for
low heterogeneity) and I2 statistics (moderate heterogen-
eity for I2 > 30% and considerable heterogeneity for
≥75%). We presented pooled ORs from random-effect
models when considerable heterogeneity was observed.
Stratified analyses by time window of vitamin D and out-
come assessment (for wheeze only), latitude, geograph-
ical region, adjustment for family history of allergic
disease, seasonality, and smoking status, methods of ex-
posure and outcome ascertainment, and risk of bias
were performed to explore the sources of heterogeneity.
Funnel plots and Egger’s test were used to explore the
possibility of publication bias. Number needed to treat
for preventing asthma by increasing from low to high
levels of vitamin D or via supplementation was esti-
mated by the baseline asthma prevalence estimates and
pooled ORs [24]. Statistical analyses were performed
with Review Manager software version 5.3 [25] and
STATA version 13.
Results
Search results
We have identified 423 potentially relevant publications
from PubMed, 855 from Embase, 36 from CNKI data-
base, 105 from CINAHL and 66 from Google Scholar.
After excluding duplicates and publication that did not
meet the inclusion criteria, three RCTs [26–28] and 33
cohort studies [20–23, 29–57] were included (Fig. 1).
Study characteristics
The main characteristics of the eligible RCTs, cohort stud-
ies and those studies excluded during full text screening are
shown in Tables 1 and 2 and Additional file 1: Table S1, re-
spectively. Two of the three RCTs were single-center trials
and recruited low-risk pregnant women. The other was a
multicenter trial enrolling pregnant women who had his-
tory of allergic disease. The dose of vitamin D administra-
tion and outcome definition varied across the three trials
(1619 participants) (Table 1). The median ages of outcome
assessment in cohort studies that reported association be-
tween blood vitamin D level and asthma, vitamin D intake
and asthma, blood vitamin D and wheeze, and vitamin D
intake and wheeze were 6 years (range 1.5–25), 5 (1.5–31),
5 (1–10), and 3 (1–10), respectively. Only two studies
assessed the outcome in adulthood [36, 57]. Of the cohort
studies, 26 studies reported data on asthma and 17 on
wheeze. Nineteen of these 26 asthma studies measured
vitamin D levels (31,940 participants from 13 cohorts were
included in the meta-analysis); the rest assessed dietary/
supplement intake (41,952 participants). A variety of oper-
ational definitions of asthma were used, including parental
reports of doctor-diagnosed asthma (n = 7), parental reports
of asthma medication use (n = 1), a combination of
both (n = 2), parental reports of doctor-diagnosed
asthma with wheezing symptom (n = 4), parental re-
ports of doctor-diagnosed asthma and wheezing and/or
asthma medication use (n = 5) and doctor-diagnosed
asthma or asthma medication use by medical record re-
view (n = 5). Two studies did not report the definition
of asthma. All 17 studies on wheeze assessed maternal
vitamin D status during pregnancy, with 12 measuring
blood vitamin D levels (8123 participants from 8 co-
horts were meta-analyzed) and 6 recorded intake (5678
participants). Most wheeze studies defined outcome
using parental reports of wheezing symptoms in the
past 12 months (Table 2).
Early life vitamin D status and asthma
Two RCTs [27, 28] reported non-significant trends of vita-
min D supplementation during pregnancy on preventing
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Fig. 1 Summary of literature search and study selection
Table 1 Characteristics of the randomized controlled trials
Reference Design Patients characteristics Intervention
(Number of participants)
Comparator
(Number of participants)
Outcomes assessment and
definition (Age of outcome
assessment)
Goldring,
2013 [26]
Single-center
non-blinded
non-placebo
RCT
Pregnant women in
London (51°N) (27 weeks
gestation, Asian, Middle
Eastern, Black and White)
without sarcoidosis,
osteomalacia, renal
dysfunction or tuberculosis
1. Daily vitamin D
(800 IU ergocalciferol
until delivery) (n = 60)
2. Bolus vitamin D
(a single oral dose of
200,000 IU
cholecalciferol (n = 60)
No treatment (n = 60) 1.Wheeze ever (ISAAC, at age 3)
2. Recurrent wheezing (≥2
episodes of reported wheezing
since birth, at age 3)
3. Wheeze in the year prior to
assessment (ISAAC, at age 3)
4. Wheeze with a positive
asthma predictive index
(loose criteria, at age 3)
Chawes,
2016 [27]
Single-center
double-blinded RCT
Pregnant women in
Denmark (55°43’N)
(≤26 gestational week)
without any endocrine,
cardiovascular, or
nephrological disorders;
or vitamin D3
(cholecalciferol) intake
more than 600 IU/d
Daily dose of 2400 IU
vitamin D3
supplementation
(24 gestational week to
1 week postpartum)
(n = 315)
Matching placebo
tablets (Camette A/S)
(24 gestational week to
1 week postpartum)
(n = 308)
1.Persistent wheeze (diagnosed
according to a previously
validated quantitative algorithm,
from birth to age 3 years)
2.Asthma (doctor diagnosed in
children fulfilling the persistent
wheeze criteria at age 3)
Litonjua,
2016 [28]
Multicenter
double-blinded
placebo RCT
Pregnant women in
Boston (52°58’N),
Washington (38°53’N),
San Diego (32°43’ N)
(age 18–39,10–18 gestational
week, nonsmoker, English or
Spanish speaking, who or
whose partner had a
history of allergic disease,
with intent to participate
for 4 years)
Daily 4000 IU of vitamin
D plus a multivitamin
with 400 IU of vitamin D
(n = 440)
Placebo (daily placebo
pill plus a multivitamin
with 400 IU of vitamin D)
(n = 436)
Asthma or recurrent
wheeze in first 3 y of life
(parental report, every 3 months)
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the development of offspring asthma (OR, 0.82; 95% CI
0.50–1.36 and HR, 0.8; 95% CI, 0.6–1.0, respectively). As
the intervention and the outcome definition were differ-
ent, we did not pool the effect size. Apart from having in-
sufficient information to assess allocation concealment,
risk of bias was low in both RCTs (Additional file 1: Figure
S1).
Figure 2 and Table 3 show the results from cohort stud-
ies as well as overall and subgroup summary ORs for the
relationship between blood vitamin D and the risk of
asthma assessed at > 5 years of age. Fix-effects ORs were
not significant for the highest vs. the lowest categories of
blood vitamin D concentrations (8 cohort studies, 28,436
participants, Fig. 2a) and for the sufficient vs. deficient
groups (5 cohort studies, 23,339 participants, Fig. 2b), with
moderate heterogeneity. The pooled estimate did not
change materially (OR 0.91, 95% CI 0.73, 1.12, I2 = 32%, for
highest vs. lowest; OR 1.02, 95% CI 0.84, 1.24, I2 = 47% for
sufficient vs. deficient groups) after excluding one
study assessing asthma in adulthood. Little heterogen-
eity was observed across subgroups, in studies meas-
uring cord blood vitamin D level, adjusted for family
history of allergic disease, or seasonality, those with
exposure measured by liquid chromatography-tandem
mass spectrometry (LC-MS/MS), and studies with
moderate risk of bias (Table 3).
Figure 3 and Table 3 show the results from cohort stud-
ies and the overall and subgroup summary ORs for the re-
lationship between blood vitamin D and the risk of
asthma assessed at ≤5 years of age. The fixed-effects ORs
were 0.81 (95% CI 0.65, 1.01, I2 = 0%, 6 cohort studies,
27,776 participants, Fig. 3a) for the highest vs. lowest cat-
egories of blood vitamin D concentrations and 0.93 for
the sufficient vs. deficient groups (95% CI 0.85, 1.03, I2 =
36%, 6 cohort studies, 27,776 participants, Fig. 3b). Al-
though higher maternal blood vitamin D level during
pregnancy was significantly associated with lower risk of
asthma assessed at ≤5 years, we did not observe any
Fig. 2 Study-specific and summary effects of pooled risk estimates of blood vitamin D levels and asthma assessed > 5 years in cohort studies.
a Highest category vs. lowest category of vitamin D; b ≥75 nmol/L vs. < 50 nmol/L
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Table 3 Summary ORs of asthma and early life blood vitamin D levels (highest versus lowest category) in cohort studies, according
to selected subgroups
Age at outcome assessment >5y Age at outcome assessment ≤5y
Subgroup Studies
(Ref. no.)
No. of
studies
OR
(95% CI)
I2 Studies
(Ref. no.)
No. of
studies
OR
(95% CI)
I2
Window of exposure assessment
During pregnancy (mother) [20, 22, 31–33, 36, 37
]
7 0.98
[0.80, 1.20]
49% [30, 32, 34, 35,
45]
5 0.79
[0.63, 0.99]
0%
Cord blood [37, 41] 2 1.03
[0.60, 1.79]
0% [23] 1 2.00
[0.48, 8.31]
–
Period of outcome assessment
At an end point (e.g. at age 1y) [20, 22, 31–33, 41] 6 0.94
[0.75, 1.17]
39% [30, 32, 34] 3 0.81
[0.64, 1.02]
20%
Up to an end point (e.g. by age 1y) [32, 36, 37] 3 1.12
[0.77, 1.64]
49% [23, 35, 45] 3 0.83
[0.40, 1.75]
17%
Latitude
Tropics or subtropics (more intense UVR)
(≤40°N/S)
[31] 1 0.58
[0.29, 1.15]
– [23, 30, 35, 45] 4 0.87
[0.61, 1.24]
0%
Temperate (40–66.5°N/S) [20, 22, 32, 33, 36, 37, 41
]
7 1.01
[0.82, 1.25]
40% [32, 34] 2 0.77
[0.57, 1.03]
54%
Region
Europe [20, 22, 32, 33, 36, 37,
41]
7 1.01
[0.82, 1.25]
40% [30, 32, 34] 3 0.81
[0.64, 1.02]
20%
USA/Canada [23] 1 2.00
[0.48, 8.31]
–
Australia [31] 1 0.58
[0.29, 1.15]
– [45] 1 0.74
[0.26, 2.14]
–
Asia [35] 1 0.40
[0.09, 1.80]
–
Adjusted for family history of atopy
No [20, 33, 36] 3 1.14
[0.88, 1.48]
67% [23, 34, 35] 3 0.70
[0.50, 0.96]
25%
Yes [22, 31, 32, 37, 41] 5 0.75
[0.55, 1.03]
0% [30, 32, 45] 3 0.93
[0.68, 1.28]
0%
Adjusted for seasonality
No [20, 22, 31] 3 0.92 [0.62,
1.37]
69% [30, 45] 2 0.87
[0.60, 1.26]
0%
Yes [32, 33, 36, 37, 41] 5 0.98
[0.78, 1.24]
30% [23, 32, 34, 35] 4 0.78
[0.59, 1.03]
35%
Adjusted for smoking statues
No [20, 22, 33] 3 1.04
[0.81, 1.33]
52% [35, 45] 2 0.60
[0.25, 1.44]
0%
Yes [31, 32, 36, 37, 41] 5 0.84
[0.60, 1.18]
44% [23, 30, 32, 34] 4 0.83
[0.66, 1.04]
26%
Outcome assessment
Maternal report of doctor diagnosed or
medication only
[22, 36, 37] 3 1.04
[0.75, 1.45]
49% [23, 30, 45] 3 0.92
[0.64, 1.32]
0%
Maternal report of doctor diagnosed plus
medication and/or wheeze symptom
[31–33] 3 0.90
[0.69, 1.16]
33% [32, 34, 35] 3 0.75
[0.57, 1.00]
31%
Doctor diagnosed or medical review [41] 1 0.61
[0.18, 2.13]
–
Other definition [20] 1 5.40
[1.09, 26.65]
–
Blood 25(OH)D measurement
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Table 3 Summary ORs of asthma and early life blood vitamin D levels (highest versus lowest category) in cohort studies, according
to selected subgroups (Continued)
Age at outcome assessment >5y Age at outcome assessment ≤5y
Subgroup Studies
(Ref. no.)
No. of
studies
OR
(95% CI)
I2 Studies
(Ref. no.)
No. of
studies
OR
(95% CI)
I2
LC-MS/MS (gold standard) [32, 33, 36, 37, 41] 5 0.98
[0.78, 1.24]
30% [23, 30, 32, 34,
45]
5 0.82
[0.66, 1.03]
2%
Other method [20, 22, 31] 3 0.92
[0.62, 1.37]
69% [35] 1 0.40
[0.09, 1.80]
–
Risk of bias
Moderate [22, 30, 32, 33, 36,
37, 41]
6 0.98
[0.80, 1.21]
13% [23, 30, 32, 34,
45]
5 0.82
[0.66, 1.03]
2%
High [20, 31] 2 1.57
[0.18, 13.80]
84% [35] 1 0.40
[0.09, 1.80]
–
Overall [20, 22, 31–33, 36,
37, 41]
8 0.96
[0.79, 1.18]
43% [23, 30, 32, 34,
35, 45]
6 0.81
[0.65, 1.01]
0%
ISAAC: The International Study of Asthma and Allergies in Children; LC-MS/MS: liquid chromatography-tandem mass spectrometry; UVR: ultraviolet radiation
Fig. 3 Study-specific and summary effects of pooled risk estimates of blood vitamin D levels and asthma assessed ≤5 years in cohort studies. a
Highest category vs. lowest category of vitamin D; b ≥75 nmol/L vs. < 50 nmol/L
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Table 4 Summary ORs of asthma and early life vitamin D intake (highest versus lowest category) in cohort studies, according to
selected subgroups
Age at outcome assessment >5y Age at outcome assessment ≤5y
Subgroup Studies
(Ref. no.)
No. of
studies
OR (95% CI) I2 Studies
(Ref. no.)
No. of
studies
OR (95% CI) I2
Window of exposure assessment
During pregnancy (mother) [50, 57] 2 1.21
[0.90, 1.62]
64% [49, 53, 55, 56] 4 0.89 [0.77, 1.04] 68%
During infancy [52] 1 0.74
[0.56, 0.96]
– [52, 54] 2 0.95 [0.85, 1.06] 27%
Period of outcome assessment
At an end point (e.g. at age 1y) [50, 52, 57] 3 0.90
[0.56, 1.45]
77% [54] 1 0.60 [0.27, 1.31] –
Up to an end point (e.g. by age 1y) [50] 1 0.60
[0.32, 1.11]
– [49, 52, 53, 55, 56] 5 0.94 [0.86, 1.02] 60%
Latitude
Tropics or subtropics (more intense UVR)
(≤40°N/S)
– – – – [54] 1 0.60 [0.27, 1.31] –
Temperate (40–66.5°N/S) [50, 52, 57] 3 0.90
[0.56, 1.45]
77% [49, 52, 53, 55, 56] 5 0.94 [0.86, 1.02] 60%
Region
Europe [50, 52, 57] 3 0.90
[0.56, 1.45]
77% [49, 52, 53, 56] 4 0.96 [0.88, 1.05] 47%
USA/Canada [55] 1 0.65 [0.46, 0.93] –
Asia [54] 1 0.60 [0.27, 1.31] –
Adjusted for family history of atopy
No [57] 1 1.33
[0.97, 1.82]
– [55] 1 0.65 [0.46, 0.93] –
Yes [50, 52] 2 0.73
[0.56, 0.94]
0% [49, 52–54, 56] 5 0.95 [0.87, 1.04] 43%
Adjusted for seasonality
No [57] 1 1.33
[0.97, 1.82]
– [53–56] 4 0.64 [0.48, 0.86] 29%
Yes [50, 52] 2 0.73
[0.56, 0.94]
0% [49, 52] 2 0.97 [0.88, 1.06] 0%
Adjusted for smoking statues
No [57] 1 1.33
[0.97, 1.82]
– [56] 1 3.16 [0.61, 16.32] –
Yes [50, 52] 2 0.73
[0.56, 0.94]
0% [49, 52–55] 5 0.93 [0.85, 1.01] 56%
Outcome assessment
Maternal report of doctor diagnosed or
medication only
[50] 1 0.60
[0.32, 1.11]
– [52, 53] 2 0.94 [0.85, 1.05] 71%
Maternal report of doctor diagnosed plus
medication and/or wheeze symptom
[50, 52, 57] 3 0.90
[0.56, 1.45]
77% [49, 55] 2 0.82 [0.55, 1.24] 77%
Doctor diagnosed or medical review – – – – [54] 1 0.60 [0.27, 1.31] –
Based on ISAAC questionnaire – – – – [56] 1 3.16 [0.61, 16.32] –
Risk of bias
Moderate [52, 57] 2 0.98
[0.55, 1.75]
87% [49, 52, 54, 56] 4 0.96 [0.88, 1.06] 14%
High [50] 1 0.63
[0.28, 1.44]
– [53, 55] 2 0.61 [0.45, 0.84] 0%
Overall [50, 52, 57] 3 0.90
[0.56, 1.45]
77% [49, 52–56] 6 0.93 [0.85, 1.02] 56%
ISAAC: The International Study of Asthma and Allergies in Children; LC-MS/MS: liquid chromatography-tandem mass spectrometry; UVR: ultraviolet radiation
Shen et al. BMC Pulmonary Medicine  (2018) 18:120 Page 12 of 18
significant associations in the stratified analyses for studies
that had more robust methodology (adjusting for further
confounders, e.g. family history of atopy, seasonality,
smoking status; blood calcifediol measured by the gold
standard LC-MS/MS; studies with lower risk of bias)
(Table 3). Six eligible cohort studies [38, 39, 43, 44, 46, 47]
analyzed blood vitamin D as a continuous variable and we
found no association with childhood asthma.
There was no association between vitamin D intake
and asthma at ≤5 years (6 cohorts, 35,257 participants)
or > 5 years (3 cohorts, 32,023 participants) (Table 4). A
significant inverse association between vitamin D intake
and asthma at ≤5 years of age emerged when we re-
stricted our analysis to studies that did not adjust for
seasonality or had high risk of bias, with low heterogen-
eity within these subgroups; and between vitamin D in-
take and asthma at > 5 years of age when we restricted
to studies that adjusted for family history of atopy, sea-
sonality or smoking status, or those that assessed out-
come in childhood (OR 0.73, 95% CI 0.56, 0.94, I2 = 0%,
25,301 participants from 2 studies, for highest vs. lowest)
(Table 4). The number needed to treat to prevent one
case of asthma was 39 (range 25–93) via maternal vita-
min D supplementation (Additional file 1: Table S2).
Studies that measured blood vitamin D concentrations
generally had a low risk of bias except for attrition bias
due to incomplete outcome data, confounding bias, and
detection bias in the assessment of prognostic factors
(Additional file 1: Figures S2 and S3). Several studies
that assessed vitamin D intake had a high risk of detec-
tion bias due to recall of vitamin D intake, confounding
bias, and attrition bias due to incomplete outcome data.
(Additional file 1: Figures S4 and S5). No evidence of
publication bias was found from the funnel plots or
Egger’s tests for blood (P = 0.963 for asthma > 5 years
and P = 0.655 for asthma ≤5 years) and intake (P = 0.913
for asthma > 5 years and P = 0.410 for asthma ≤5 years)
(Additional file 1: Table S3).
Early life vitamin D status and wheeze
All three RCTs [26–28] used wheeze as primary outcome
(one combined with asthma [28]). Two RCTs found no
definitive effect of vitamin D supplementation during
pregnancy on wheeze among offspring by 3 years of age
Fig. 4 Study-specific and summary effects of pooled risk estimates of blood vitamin D levels and wheeze in cohort studies. a Highest category vs.
lowest category of vitamin D; b ≥75 nmol/L vs. < 50 nmol/L
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(OR 0.86; 95% CI 0.49, 1.50; HR 0.76; 95% CI 0.52, 1.12)
and one found a borderline statistical significance associ-
ation (HR 0.8; 95% CI 0.6, 1.0). We did not perform
pooled analysis for wheeze because of the major differ-
ences in intervention. Risks of performance and attrition
bias were considered to be high due to missing outcome
data and the lack of blinding in the trial conducted by
Goldring et al. [26] (Additional file 1: Figure S1).
We did not observe significant association between
maternal vitamin D concentrations during pregnancy
and offspring wheeze in cohort studies (8123 partici-
pants from 8 studies, OR 0.91, 95% CI 0.76, 1.09 for
highest vs. lowest levels, I2 = 25%; 2324 participants from
3 studies, OR 0.91, 95% CI 0.70, 1.19 for ≥75 nmol/L vs.
< 50 nmol/L, I2 = 0%) (Fig. 4). Similar results were
observed in stratified analyses (Table 5). Within-group
inconsistency disappeared or was attenuated in studies
that measured vitamin D intake during pregnancy or ad-
justed for family history of atopy or seasonality or blood
calcifediol measured by LC-MS/MS or studies with
moderate risk of bias. The overall fixed-effects OR of
wheeze relating to maternal vitamin D intake was 0.66
(95% CI 0.53, 0.82; 5238 participants from 6 studies,
I2 = 52%, Table 5). The association remained statistically
significant when restricting to studies that: assessed out-
come at or before 3 years of age and after 3 years of
age, were conducted in a temperate area, adjusted for
family history of atopy or seasonality, and those that had
lower risk of bias. The Baiz paper [38] did not find an
association in early transient, late onset or persistent
wheeze, while Camargo et al. [39] reported a significant
protective effect by 5 years of age (OR 0.95, 95% CI 0.91,
Table 5 Summary ORs of wheeze and vitamin D status (highest versus lowest category) in cohort studies, according to selected
subgroups
Early life blood vitamin D levels Early life vitamin D intake
Subgroup Studies
(Ref. no.)
No. of
studies
OR
(95% CI)
I2 Studies
(Ref. no.)
No. of
studies
OR
(95% CI)
I2
Window of exposure assessment
During pregnancy (mother) [22, 30, 31, 33, 37] 5 0.93 [0.76, 1.12] 9% [21, 48, 49, 51, 54,
55]
6 0.66 [0.53, 0.82] 52%
Cord blood [21, 40, 42] 3 0.83 [0.51, 1.35] 58% – – – –
During infancy (infant) [42] 1 1.88 [0.89, 3.98]
Age at outcome assessment
≤3y [21, 29, 30, 37, 40, 42] 6 0.93 [0.77, 1.12] 26% [21, 48, 51, 54] 4 0.68 [0.53, 0.88] 63%
> 3y [22, 30, 31, 33, 37] 5 1.09 [0.89, 1.33] 11% [49, 55] 2 0.57 [0.35, 0.93] 48%
Latitude
Tropics or subtropics
(more intense UVR) (≤40°N/S)
[21, 30, 31] 3 0.83 [0.60, 1.14] 47% [21, 48, 54] 3 0.81 [0.61, 1.07] 7%
Temperate (40–66.5°N/S) [22, 33, 37, 40, 42] 5 0.95 [0.77, 1.18] 21% [49, 51, 55] 3 0.47 [0.33, 0.68] 35%
Adjusted for family history of atopy
No [40] 1 0.36 [0.14, 0.89] – [21, 55] 2 0.84 [0.47, 1.49] 46%
Yes [21, 22, 30, 31, 33, 37,
42]
7 0.95 [0.79, 1.14] 0% [48, 49, 51, 54] 4 0.63 [0.49, 0.80] 61%
Adjusted for seasonality
No [22, 30, 31, 40] 4 0.78 [0.60, 1.01] 51% [21, 48, 54, 55] 4 0.79 [0.61, 1.03] 0%
Yes [21, 33, 37, 42] 4 1.05 [0.82, 1.33] 0% [49, 51] 2 0.37 [0.24, 0.58] 0%
Blood 25(OH)D measurement
LC-MS/MS (gold standard) [21, 30, 33, 37, 40, 42] 6 0.97 [0.79, 1.19] 10% – – – –
Other methods [22, 31] 2 0.76 [0.53, 1.10] 60% – – – –
Risk of bias
Moderate [22, 30, 33, 37] 4 0.99 [0.81, 1.21] 0% [48, 49, 51, 54] 4 0.63 [0.49, 0.80] 61%
High [21, 31, 40, 42] 4 0.69 [0.47, 1.01] 52% [21, 55] 2 0.84 [0.47, 1.49] 46%
Overall [21, 22, 30, 31, 33, 37,
40, 42]
8 0.91 [0.76, 1.09] 25% [21, 48, 49, 51,
54, 55]
6 0.66 [0.53, 0.82] 52%
LC-MS/MS: liquid chromatography-tandem mass spectrometry
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0.99), but this has not been consistent in earlier time
windows reported in the studies by Camargo et al. [39]
and Visness et al. [44]
The 12 cohort studies that investigated blood vitamin
D levels and wheeze were evaluated to have low risk of
bias, in terms of participant selection, exposure assess-
ment, and window of outcome assessment and
co-intervention. Some studies had high or unclear risk
of confounding bias, detection bias and attrition bias
(Additional file 1: Figure S6, a and b). Overall, the stud-
ies on vitamin D intake had higher risk of bias, due to
their inadequacy in exposure assessment, assessment
and adjustment for prognostic factors, and outcome
follow-up (Additional file 1: Figure S7, a and b). There
was no evidence of publication bias from the funnel
plots or Egger’s tests for blood (P = 0.772) and intake
(P = 0.954) (Additional file 1: Table S3).
Discussion
This meta-analysis of cohort studies found no statisti-
cally significant association between vitamin D levels in
maternal or cord blood or intake in early life and asthma
either at > 5 or ≤ 5 years of age, with no evidence of pub-
lication bias. Of the cohort studies included, only two
studies assessed asthma in adulthood [36, 57]. The ex-
clusion of these two studies did not change the pooled
estimate for blood vitamin D levels, while a significant
inverse association between early life vitamin intake and
childhood asthma at > 5 years emerged. We found no
association between early life vitamin D level and risk of
wheeze in later life. On the other hand, findings from
cohort studies seemed to suggest a lower risk of wheeze
associated with maternal vitamin D intake during
pregnancy.
Variations in the intervention and outcome definition
in three identified RCTs made it difficult to pool the ef-
fect size for wheeze or asthma associated with vitamin D
supplementation during pregnancy. Two more recent
trials [27, 28] with lower risk of bias also found
non-statistically significant benefit for persistent/recur-
rent wheeze or asthma in the first 3 years of life. The
results of RCTs were in line with the results of our
meta-analysis of cohort studies, where we found
non-significant trends of vitamin D supplementation
for preventing offspring asthma at ≤5 years. However,
our findings from cohort studies also suggest that
early-life vitamin D intake may have an effect on child-
hood asthma at age > 5 years and childhood wheeze.
Longer follow-up time for assessing the effect of vita-
min D intake against asthma is required in future
RCTs to confirm these results [58].
There are two opposing views regarding the relationship
between vitamin D exposure and asthma. One school of
thought, based on growing epidemiological evidence, hy-
pothesized a link between vitamin D deficiency in early life
and development of asthma and other allergic diseases [59],
thought to have begun as sunlight exposure decreased with
industrialization and urbanization. Others argued, however,
that the current asthma and allergic disease pandemic
might have been the consequence of widespread vitamin D
supplementation in food, backed by some historical evi-
dence [60]. Coincidentally, both low and high levels of vita-
min D were reported to be related to asthma, in a
U-shaped manner [32]. Another study by Rothers et al. also
found that both low (< 50 nmol/L) and high (≥100 nmol/L)
levels of cord blood calcifediol were associated with in-
creased IgE, which was related to subsequent risk of
wheeze/asthma [23]. In the present meta-analysis, the in-
consistent results from studies assessing vitamin D either in
blood or intake for childhood asthma/wheeze risk may be
explained by the previously reported non-linear association
between blood vitamin D3 and childhood asthma, which
tends to be non-statistically significant by comparing the
highest with lowest vitamin D levels [32]. However, the di-
chotomized exposure in the present study limited the ex-
ploration of non-linear association.
The sources of heterogeneity, as indicated by the re-
sults from stratified analyses were: window of exposure
assessment, whether family history of atopy or seasonal-
ity have been adjusted for, definition of outcome, risk of
bias, and the method of assessing blood calcifediol. As
suggested by Autier et al. [61], vitamin D level could be
a biomarker and proxy for overall health and wellbeing
of mothers and infants. However, as most of the cohort
studies included did not adjust for health status of the
participants, we were unable to exclude such potential
confounding. In most of the studies included, tobacco
smoking was adjusted for in the analysis, but other im-
portant confounders including family history of atopic
diseases, seasonal variations in blood vitamin D levels,
sedentary lifestyle and obesity [62–64] were less com-
monly considered. Nevertheless, results from our sensi-
tivity analysis on studies reporting blood vitamin D level,
which included only studies that adjusted for family his-
tory and seasonal variations, showed no material differ-
ence in the summary estimates compared with our main
findings. Three of the cohort studies [35, 42, 47] mea-
sured serum calcifediol in both prenatal and postnatal
periods, but these studies analyzed the associations be-
tween vitamin D measured at different time points with
outcome separately and failed to explore the effect of
persistent vitamin D deficiency on asthma. While the
half-life of serum calcifediol is only about two weeks
[65], it is possible that such misclassification in vitamin
D status measured at only one time point could have
biased the findings towards the null. A recent study con-
ducted by Hollams et al. used mixed-effects logistic
Shen et al. BMC Pulmonary Medicine  (2018) 18:120 Page 15 of 18
regression and found no longitudinal association be-
tween calcifediol concentrations as a continuous variable
and asthma from 3 to 10 years of age [46].
On the issue of case definition, ascertaining childhood
asthma in epidemiological studies has been challenging
given the lack of definitive diagnostic criteria [66, 67].
Most studies defined asthma by either maternal report
of doctor-diagnosed asthma, asthma medications use, or
a combination of doctor-diagnosed asthma and either
asthma medication or wheezing symptoms within the
past year. Although not without caveats, such as
under-reporting both diagnosed and undiagnosed condi-
tions [68] and variable agreement with clinical records
[67], these definitions have been widely used in research
[69]. In two studies asthma definition was not specified,
adding further variability to outcome assessment and in-
creased heterogeneity in our pooled analyses.
In general, studies investigating blood vitamin D levels
had relatively low risk of bias in most domains except
for confounding, detection, and attrition biases, whereas
studies that used food frequency questionnaire to quan-
tify vitamin D intake were at risk of misclassification bias
as pregnant women often had to recall their dietary his-
tory from a few months previous.. Apart from detection
bias, most vitamin D intake studies were also at risk of
attrition bias for their inadequate follow-up duration or
unknown difference between missing and available out-
come data, as well as confounding bias in some studies
which did not include major confounders. In addition to
variation over time, different methods of blood vitamin D
level quantification employed in different studies might
also introduce inter-study variability. In the stratified ana-
lysis, we compared the risk estimates derived from studies
that used the gold standard LC-MS/MS with those using
other methods and found no material difference between
the pooled estimates. Studies that investigated antenatal
vitamin D intake and asthma at > 5 years of age tended to
be small and their inclusion in the meta-analysis may ex-
plain the weak evidence observed.
Compared to previous related systematic reviews [11–13,
70], we have identified more cohort studies and included
two recently published RCTs in the analysis. Only six cohort
studies [20, 22, 23, 30, 33, 39] measuring maternal serum cal-
cifediol during pregnancy or from cord blood and asthma
risk were identified by Cassim et al. [70], but we have in-
cluded 13 more studies [31, 32, 34–38, 41, 43–47], plus an
additional 13 cohort studies [21, 22, 29–31, 33, 37–40, 42,
44, 46] to explore the association between calcifediol level in
maternal blood or cord blood and wheeze risk. As a conse-
quence of our more comprehensive approach in including
various exposure metrics (intake and blood level, both mater-
nal and in infant) in the search strategy and a critical risk of
bias assessment using the risk of bias tool recommended by
the Cochrane Collaboration [17, 18], we were able to
demonstrate the existence of heterogeneity between studies
in the findings, which lead us to a more conservative conclu-
sion. In addition, we further studied the association between
antenatal or early postnatal vitamin D level and asthma and
wheeze using commonly accepted clinical cut-off values. We
found no difference of risk of asthma or wheeze between suf-
ficient and deficient vitamin D level groups, implying the op-
timal threshold for bone health may not necessarily be
applicable for the respiratory and immune systems.
One of the limitations of this work is that we were un-
able to retrieve sufficient information for calculating
pooled estimates from six eligible studies that analyzed
vitamin D level as a continuous variable. We were able to
identify one study that has examined infant blood vitamin
D levels and their relationship to wheeze but none for
asthma. Studies investigating the association between in-
fant vitamin D levels and risk of childhood asthma should
be encouraged, with designs that minimize detection, con-
founding, and follow-up biases.
Conclusions
The pooled estimates from cohort studies show no associ-
ation between antenatal blood vitamin D level and asthma/
wheeze in later life. On the other hand, although the inter-
ventional studies found a non-statistically significant benefit
for asthma/wheeze in first 3 years of life, the pooled esti-
mates from cohort studies suggest that early life vitamin D
intake may have an effect on childhood asthma > 5 years or
childhood wheeze. Should that be the case, this may point
to a cost-effective intervention for childhood asthma. Fur-
ther trials with enough power and longer follow-up time
should be conducted to confirm the results.
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